NPCE reports 21% revenue growth; FDA IGE approval could lift market
NPCE said it delivered 21% revenue growth and a robust patient pipeline. It cited FDA approval for IGE that could expand the addressable market by 20%, alongside AI-driven tools and remote monitoring.
NPCE reported a 21% increase in revenue, with strong core growth and a robust patient pipeline. FDA approval for IGE could expand the addressable market by 20%, with compelling clinical data cited as support for broader adoption. AI-driven tools and remote monitoring are intended to reduce friction and support scalable growth.